Malignancy and myositis, from molecular mimicry to tumor infiltrating lymphocytes.


Journal

Neuromuscular disorders : NMD
ISSN: 1873-2364
Titre abrégé: Neuromuscul Disord
Pays: England
ID NLM: 9111470

Informations de publication

Date de publication:
11 2019
Historique:
received: 06 06 2019
revised: 21 09 2019
accepted: 23 09 2019
pubmed: 23 10 2019
medline: 7 7 2020
entrez: 23 10 2019
Statut: ppublish

Résumé

Cancer-associated dermatomyositis provides a unique opportunity to explore the relationship between autoimmunity and cancer. In this review, we describe the related epidemiological issues, considering the various currently accepted myositis phenotypes, their link with cancer, and the possible mechanisms leading to this relationship. We discuss current evidence regarding the role of molecular mimicry, somatic DNA tumor mutations, and the PD-1/PD-L1 pathway in the association between cancer and myositis. We also review tumor-infiltrating lymphocytes as a relevant factor to be evaluated in cancer-associated myositis, their interaction with tumor neoantigens, and the tumor mutational burden, all of which have implications for the treatment of these patients with immunotherapy. Finally, we discuss clinical scenarios related to the relationship between cancer and myositis, delineating a comprehensive theory linking autoimmunity and cancer.

Identifiants

pubmed: 31635909
pii: S0960-8966(19)31134-4
doi: 10.1016/j.nmd.2019.09.014
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

819-825

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Albert Selva-O'Callaghan (A)

Internal Medicine Department, Autoimmune Systemic Diseases Unit, Vall d'Hebron General Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain. Electronic address: aselva@vhebron.net.

Javier Ros (J)

Medical Oncology Department, Vall d'Hebron General Hospital, Barcelona, Spain.

Albert Gil-Vila (A)

Internal Medicine Department, Autoimmune Systemic Diseases Unit, Vall d'Hebron General Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain.

Gemma Vila-Pijoan (G)

Immunology Department, Vall d'Hebron General Hospital, Barcelona, Spain.

Ernesto Trallero-Araguás (E)

Rheumatology Unit, Vall d'Hebron General Hospital, Barcelona, Spain.

Iago Pinal-Fernandez (I)

National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Johns Hopkins University School of Medicine, Baltimore, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH